BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22363760)

  • 1. Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.
    Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry JP; Guertler R; Hornung D; Mueller R; Fink DA; Hacker NF; Heinzelmann-Schwarz VA
    PLoS One; 2012; 7(2):e31885. PubMed ID: 22363760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.
    Horvath LG; Henshall SM; Kench JG; Saunders DN; Lee CS; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
    Clin Cancer Res; 2004 Jan; 10(2):615-25. PubMed ID: 14760084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
    Saran U; Arfuso F; Zeps N; Dharmarajan A
    BMC Cell Biol; 2012 Oct; 13():25. PubMed ID: 23039795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours.
    Drake J; Shearwood AM; White J; Friis R; Zeps N; Charles A; Dharmarajan A
    Eur J Gynaecol Oncol; 2009; 30(2):133-41. PubMed ID: 19480240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
    Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
    PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic demethylation of sFRPs, with emphasis on sFRP4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.
    Deshmukh A; Arfuso F; Newsholme P; Dharmarajan A
    Int J Biochem Cell Biol; 2019 Apr; 109():23-32. PubMed ID: 30710752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
    He B; Lee AY; Dadfarmay S; You L; Xu Z; Reguart N; Mazieres J; Mikami I; McCormick F; Jablons DM
    Cancer Res; 2005 Feb; 65(3):743-8. PubMed ID: 15705870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor role of sFRP‑4 in hepatocellular carcinoma via the Wnt/β‑catenin signaling pathway.
    Wu Q; Xu C; Zeng X; Zhang Z; Yang B; Rao Z
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
    Hendrix ND; Wu R; Kuick R; Schwartz DR; Fearon ER; Cho KR
    Cancer Res; 2006 Feb; 66(3):1354-62. PubMed ID: 16452189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells.
    Carmon KS; Loose DS
    Mol Cancer Res; 2008 Jun; 6(6):1017-28. PubMed ID: 18567805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
    Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
    Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
    Yoshioka S; King ML; Ran S; Okuda H; MacLean JA; McAsey ME; Sugino N; Brard L; Watabe K; Hayashi K
    Mol Cancer Res; 2012 Mar; 10(3):469-82. PubMed ID: 22232518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
    Wu G; Liu A; Zhu J; Lei F; Wu S; Zhang X; Ye L; Cao L; He S
    Oncotarget; 2015 Oct; 6(30):28882-94. PubMed ID: 26337084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demethylation of the
    Li H; Zhao J; Sun J; Tian C; Jiang Q; Ding C; Gan Q; Shu P; Wang X; Qin J; Sun Y
    Mol Cancer Res; 2021 Sep; 19(9):1454-1464. PubMed ID: 34016745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH
    Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.
    Burkhalter RJ; Westfall SD; Liu Y; Stack MS
    J Biol Chem; 2015 Sep; 290(36):22143-54. PubMed ID: 26175151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
    Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
    Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
    Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
    Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short peptide domains of the Wnt inhibitor sFRP4 target ovarian cancer stem cells by neutralizing the Wnt β-catenin pathway, disrupting the interaction between β-catenin and CD24 and suppressing autophagy.
    Sundaram SM; Varier L; Fathima KZ; Dharmarajan A; Warrier S
    Life Sci; 2023 Mar; 316():121384. PubMed ID: 36646377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.